APA (7th ed.) Citation

Zheng, Z., Xie, D., Su, H., Lin, B., Zhao, L., Deng, X., . . . Xie, C. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors. SAGE Publishing.

Chicago Style (17th ed.) Citation

Zheng, Zhen, et al. Treatment Outcome Comparisons Between Exons 19 and 21 EGFR Mutations for Non-small-cell Lung Cancer Patients with Malignant Pleural Effusion After First-line and Second-line Tyrosine Kinase Inhibitors. SAGE Publishing.

MLA (9th ed.) Citation

Zheng, Zhen, et al. Treatment Outcome Comparisons Between Exons 19 and 21 EGFR Mutations for Non-small-cell Lung Cancer Patients with Malignant Pleural Effusion After First-line and Second-line Tyrosine Kinase Inhibitors. SAGE Publishing.